Study: docs eager for new obesity pills

Share this article:
With a race on to develop a new obesity treatment, Ipsos surveyed primary care doctors and found receptivity to all three clinical-stage products.

Between one-half and two-thirds of PCPs said they would likely prescribe any of the three drugs to treat their obese or overweight patients: Qnexa from Vivus, Lorqess/lorcaserin from Arena Pharmaceuticals or Contrave, from Orexigen Therapeutics.

The results were derived from an Ipsos online survey conducted as part of a Vantis Health Files (VHF) project in April 2010 among 1,500 (> 125 exposures per product) PCPs. VHF is a syndicated service designed to provide insights into the market potential for new healthcare products.

Among the three candidates, slated for FDA review within the next few months, Ipsos forecasted US retail sales to exceed $400 million annually within three to five years of launch and that Lorqess/lorcaserin has the best chance of approval.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?